Insulin analogues and other developments in insulin therapy for diabetes (Q35164710)

6 August 2017

1 reference

title

Insulin analogues and other developments in insulin therapy for diabetes (English)

1 reference

6 August 2017

1 reference

Vincent McAulay

1

1 reference

PubMed ID

12831339

6 August 2017

Brian M Frier

series ordinal

2

1 reference

PubMed ID

12831339

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Expert Opinion on Pharmacotherapy

6 August 2017

1 reference

6 August 2017

4

1 reference

6 August 2017

7

1 reference

6 August 2017

1141-1156

1 reference

Insulins today and beyond

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

The impact of smoking on inhaled insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Metabolic and immunologic effects of insulin lispro in gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1141

10.1517/14656566.4.7.1141

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12831339